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Abstract: Proteinopathies are diseases caused by factors that affect proteoform conformation. As
such, a prevalent hypothesis is that the misincorporation of noncanonical amino acids into a pro-
teoform results in detrimental structures. However, this hypothesis is missing proteomic evidence,
specifically the detection of a noncanonical amino acid in a peptide sequence. This review aims to
outline the current state of technology that can be used to investigate mistranslations and misincor-
porations whilst framing the pursuit as Misincorporation Proteomics (MiP). The current availability
of technologies explored herein is mass spectrometry, sample enrichment/preparation, data analysis
techniques, and the hyphenation of approaches. While many of these technologies show potential,
our review reveals a need for further development and refinement of approaches is still required.
Keywords: misincorporation; non protein amino acids; post translational modifications
1. Introduction
The “central dogma” of molecular biology suggests that the translation of one gene
results in the expression of a single protein [1]. However, translated proteins are known to
exist as multiple biological variants or proteoforms [2]. These proteoforms are the result of
modifications to the polypeptide chain, including the addition, subtraction, or alteration
of chemical groups. Such modifications can endow proteoforms with biological activity
or an altered function varying from the original proteoform [3]. Any modification that
occurs to a proteoform once already translated is termed a post-translational modification
(PTM), generating a new and distinct proteoform, adding the advantage of complexity to
the proteome [4–6].
Additionally, and importantly for this review, variant proteoforms may be generated
by mechanisms other than post-translational modification. During protein translation,
an incorrect amino acid may be inserted into the growing peptide chain, resulting in a
modification in the final proteoform. Such errors generate new, non-native proteoforms
that have the potential to cause harm to the cell [7,8]. The mistranslational error rate
reported in Escherichia coli (E. coli) is between 0.5–5% at any amino acid position [8]. This
occurrence of errors in translation during synthesis can generate a new proteoform in the
same way that cleavage or PTM can e.g., N-terminal methionine excision [8–10]. However,
instead of providing an advantage to the cell, proteoforms produced through mistranslation
often present a burden, as they are unpredictably generated with the resulting non-native
proteoforms prone to misfolding [11,12]. To overcome this, the cell has sophisticated
machinery to identify and degrade these proteoforms [13].
The “misincorporation” of incorrect amino acids into a proteoform need not be limited
to the 20 canonical amino acids used in proteoform synthesis. Thousands of synthetic and
naturally occurring nonprotein amino acids (NPAAs) exist, also referred to as “nonpro-
teogenic”, “noncanonical”, “noncoded”, or “non-natural” [14]. The infiltration of NPAAs
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into the protein translation process adds further opportunity for mistakes to be made
during translation, resulting in distinct and unintentionally produced proteoforms. Such
misincorporation can cause aberrant modifications to proteoform structure, with biological
ramifications for the cell or organism that can perturb normal cellular function. It has
been shown that misincorporation of an NPAA can alter the 3D structure of a proteoform,
resulting in aggregation [15]. Such misfolding and aggregation of proteoforms is known
to be a hallmark of numerous degenerative neurological diseases [16] and for some dis-
eases, an association already exists between exposure to NPAAs and disease development.
This includes motor neuron disease (MND) [17,18], multiple sclerosis [19,20] and neuro-
lathyrism [21,22]. As such, the exploration of NPAA misincorporation into proteoforms to
date has largely focused on their underlying potential to trigger proteinopathies and cause
neurodegeneration. To describe the study of NPAA misincorporation into the proteome, we
introduce the term Misincorporation Proteomics (MiP), whereby during protein translation,
a genetically encoded canonical amino acid is replaced by a NPAA.
2. Amino Acid Misincorporation
Protein translation involves the cognate amino acid (AA) being charged by its ap-
propriate aminoacyl tRNA synthetase (aaRS; Figure 1). The charging is enabled by the
hydrolysis of adenosine triphosphate (ATP) and allows the formation of an AA/aaRS/AMP
complex. The cognate transfer RNA (tRNA) then binds to this aaRS/AA/AMP complex
and an aminoacyl ester bond forms, transferring the aminoacyl group to the tRNA and
releasing AMP [23,24].
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Figure 1. The transfer of amino acids (AA) onto tRNA through tRNA synthetase (aaRS) in the
presence of ATP. ATP is converted to AMP activating the aaRS with the AA, an tRNA is then bound
o the AA of the AA/aaRS/AMP complex ubs quently the now charged tRNA dissociates.
Correct binding of amino acid to its aaRS is dependent on the fit between the amino
acid and enzyme binding pocket [25]. If an incorrect amino acid binds the aaRS, this
can be removed by a series of proofreading functions known as pre- and post-transfer
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editing (Figure 2). Pre-transfer editing occurs before tRNA binds to the charged amino acid.
Removal of the charged amino acid has been suggested to occur via various mechanisms,
including selective release by the aaRS enzyme, translocation to a separate hydrolytic
editing site on the enzyme, or hydrolysis at the primary active site of the aaRS [25,26].
Post-transfer editing occurs after the mischarged amino acid is attached to tRNA and
involves the hydrolysis of the ester bond between the two. This can occur via cis-editing
at a separate editing domain, by trans-editing factors that resample mischarged amino
acid tRNA at the aaRS, or by free trans-editing factors [25,26]. The extent to which pre-
and post-transfer editing occurs in human aaRS enzymes is poorly understood, as are the
mechanisms by which pre- and post-transfer editing select for misincorporations of NPAAs
in particular.
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Despite the presence of checks to avoid incorrect amino acid incorporation, misincor-
poration can still occur. The misincorporation rate at any amino acid position is quoted
as 1/10,000 when considering only the 20 canonical amino acids [9]. However, this rate
may be higher when considering NPAAs could be present within the available pool of
amino acids. The misincorporation of an NPAA into a growing polypeptide chain through
its mischarging onto the aaRS, followed by the failure of the aaRS to remove the mis-
charged NPAA, allows for the non-native proteoform to be released. Additionally, an
NPAA may outcompete the canonical amino acid for binding, especially when there is a
higher concentration of NPAA present [15,18,27,28]. Depending on the position of NPAA
misincorporation and the canonical amino acid that was replaced, there may be a conforma-
tional change in the proteoform, which predisposes it to misfolding and aggregation. Other
issues may include replacement of amino acid residues that are essential sites for activity
or post-translational modifications (PTM) in that proteoform. Such alterations to the amino
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acid sequence can hinder a cells ability to operate, as the proteoforms may be nonfunctional,
aggregate, or even acquire a toxic gain of function. An example of the impacts which NPAA
misincorporation may cause is the neurological disease multiple sclerosis, the development
of which has hypothesised links to misincorporation of the NPAA azetidine-2-carboxylic
acid (azetidine), a proline analogue derived from the common agricultural crop sugar beet
(beta vulgaris), into myelin basic protein [27]. The consequences posed by the misincorpo-
ration of NPAAs may be broad and unpredictable, making it important for the cell to have
defences and solutions to this problem.
In addition to the checks during polypeptide synthesis that help to both initially
avoid the mischarging of amino acids and to hydrolyse any mischarged amino acids from
a tRNA, there are also checks in place following polypeptide synthesis that detect and
remove misfolded proteoforms. Chaperones attempt to refold proteoforms to the correct
conformational structure and if unsuccessful, degradation pathways such as the proteasome
and autophagy are utilised [28]. The failure or bypassing of these checks altogether should
trigger cell death. The toxic species of proteoform produced by the misincorporation
process may aggregate and self-propagate, forming the basis for proteinopathies and
NPAA pathologies [29–31]. As the induction of apoptosis/necrosis occurs when the burden
of protein aggregates reaches a threshold, this presents a bigger problem for terminally
differentiated cells such as neurons. Such cells cannot share the burden of aggregated
proteins amongst daughter cells by dividing and must bear the burden fully, increasing
their susceptibility to NPAA pathologies [31]. This may explain why diseases associated
with NPAAs tend to be neurological in nature, and why it is of growing importance to
investigate misincorporation and its consequences.
3. The Identification of NPAAs Misincorporation
The measurements of NPAA misincorporation to date have primarily relied on in-
ference methodologies, indicating NPAA presence but not location, rather than the direct
sequence localisation of a peptide or protein containing a NPAA (Table 1). Studies by Fow-
den and Richmond [32] in the 1960s were part of the foundational works for the exploration
of NPAA misincorporation [33–35]. Here, NPAAs are recognised as structural analogues
of canonical amino acids [36] with various toxic effects and as metabolites arising from
their mimicry and competition with the canonical amino acids they resemble. This resulted
in the term “antimetabolite” being used to describe these toxic NPAAs, with the arginine
analogue Canavanine exemplifying this [37].
Various methods were employed during these early studies to investigate the misin-
corporation of NPAAs. This included the addition of NPAAs and canonical amino acids
in different ratios to growing bacterial cultures to observe toxicity and infer competition
between NPAA and canonical amino acids [32,38,39]. Such studies offered insight into the
similarity of some NPAAs to specific canonical amino acids and therefore an understanding
of what pathways would be most affected by the NPAA. Since these early studies, there
has been a range of methods used to infer mistranslation and misincorporation of amino
acids generally, including NPAAs. Some approaches included studying misincorporation
at the tRNA level using radiolabelled amino acids and tRNA microarrays to detect mis-
acylation [40]. Such methods have shown that the NPAA Beta-methyl-amino-L-alanine
(BMAA) charges to both alanine and serine tRNAs and bypasses the proof-reading ability
of the alanine aaRs, suggesting misincorporation at alanine positions [41,42]. An alternate
approach that has proved popular is the use of radiolabelled amino acids, particularly
in E. coli. Detection of a radioactive signal within isolated protein infers that the labelled
amino acid has been incorporated, replacing the canonical amino acid, or is associated with
the protein fraction. Examples include detection of radiolabelled cysteine in cysteine-free
flagellin in E. coli [43]. Similar studies in E. coli [44,45] and rabbit reticulocytes [46] have
also used this method.
Another method of inferring amino acid misincorporation is to study the effects on the
proteoforms themselves if misincorporation occurs. This includes measuring changes in
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the isoelectric point of a proteoform due to different amino acid residues being present [47],
or restoration of enzymatic activity, including fluorescence, of the resulting proteoform
species [48–53]. Other methods include inference of incorporation by an inability to
detect free COOH or NH2 groups of the NPAA unless first hydrolysed from protein
(dinitrophenyl assay). Alternatively, the use of detectors coupled to chromatographic
and ionophoric separation have also been used for the identification of NPAAs from a
protein hydrolysate [36]. While these various techniques have provided useful information,
many also rely on the use of bacterial systems, limiting their application in mammalian
research. Most importantly, all these methods offer only an indirect measurement of
misincorporation and cannot definitively characterise the misincorporations of NPAAs.
For a review of these techniques, refer to the work of Ribas de Pouplana et al. [54].
There are also direct methods of detecting misincorporation that involve mass spec-
trometry. This provides the opportunity to localise a NPAA in a peptide sequence and
identify misincorporation of incorrect amino acids based on side-chain modifications or the
use of a modified database algorithm [55,56]. Identification of NPAAs in the hydrolysate of
protein fractions via high-pressure liquid chromatography (HPLC) coupled to either mass
spectrometric (MS) (including tandem (MS/MS)) [41], or spectrophotometric detectors
(such as ultraviolet-visible spectroscopy (UV-VIS)), is a routine technique. Additionally,
there has been an analytical method developed for assaying misincorporation in overex-
pressed proteins in E. coli and yeast called MS-READ, which utilises a genetically modified
overexpression model combined with affinity purification [25]. In a similar manner, ESI-MS
has been used to study the incorporation of L-3,4-dihydroxyphenylalanine (L-DOPA) in
proteins expressed in E. coli. However, although a mass shift corresponding to L-DOPA
was observed in the protein and tryptic peptides, fragmentation of the trypsin-generated
peptides was not performed, preventing localisation of the L-DOPA in the peptide se-
quence [57]. The use of hydrolysis and detection methods indicating NPAA presence do
not provide proteoform sequence information which is essential in studying the effects of
NPAAs on biology.
Table 1. Direct and indirect methods used to determine NPAA misincorporation.
Analysis Type Method of Analysis Ref.
Direct
-MS mass shift analysis [57]
-MS/MS peptide spectral analysis NPD
-MS-READ [25]
Indirect
-Hydrolysed amino acid analysis [41]
-Radio-labelled amino acid analysis [40]
-Amino acid competition studies [32]
-tRNA micro-assay [40]
-Proteoform isoelectric point analysis [47]
-Enzymatic activity assays [48]
-Dinitrophenyl assay [36]
NPD stands for no published data.
The sensitivity of the methods that can be employed to explore misincorporation
varies with the more sensitive methods sacrificing direct site localisation for a decreased
limit of detection. These highly sensitive methods include radiolabelling experiments,
amino acid analysis of protein hydrolysate, ELISAs and antibody-based microscopy. These
methods can be employed alongside exploratory proteomic methods and the usage of
targeted mass spectrometry for quantification can also be employed following identification
of misincorporation species. When applied to the quantification of the misincorporation
species, indirect methods like amino acid hydrolysis have sensitivity in the parts-per-billion
(ppb) or pictogram range. Antibody-based detection methods using coupled enzyme-based
reporters, such as horseradish peroxidase (HRP), could theoretically detect a single antigen
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molecule if enough substrate is converted to a detectable product but detection limits will
vary with antibodies and variation of molecular structure around the NPAA site.
As the advancement of proteomics has led to an increase in the ability to detect and
characterise canonical amino acid mistranslation, the applications of the techniques have
diversified. This review will firstly outline key considerations in the exploratory analysis
of MiP, including experimental considerations and biological assumptions that should
be understood before utilising certain methods and models. Secondly, a summary of the
mass spectrometric technologies that have become available in the pursuit of investigating
these misincorporations will be discussed, including targeted global proteomics, data-
independent acquisition technologies, precursor ion scanning, and unique instrument
system configurations. Considerations for sample processing and potential enrichment
strategies that can be employed or require development are introduced before a discussion
of the diverse range of pipelines, processes, and data analysis suites originally designed
for PTM identification that can be repurposed for MiP. While the bulk of this paper will
focus on the ramifications for human samples, many of the techniques discussed are still
applicable to a large array of different sample types. From the outset of a study, it is
essential to understand that for the generation of high-quality data in MiP, there needs to
be enough of the NPAA misincorporation in a proteoform at a specific location prior to
protein extraction as analysis methods in proteomics, such as gel electrophoresis and mass
spectrometry, are concentration sensitive technologies.
4. Key Considerations in Mistranslation Proteomics
The nature of NPAA misincorporation is random or stochastic and when considering
a single site of incorporation, and excluding mechanistic interference, the proportion of
proteoforms containing a misincorporation will be several fold less abundant given the
highest observed error rates of 10% in canonical amino acid substitution at a single site
substitution (Asn->Asp) in E. coli [55]. Additionally, detection becomes even more difficult
when considering that misincorporation may randomly occur at more than one site in a
peptide sequence, resulting in a wider variety of proteoforms, and thus peptidoforms, all
at a lower abundance. For example, an incorporation rate of 1 in 1000 with three possible
sites would have a 1 × 10−12 abundance in comparison to the unmodified molecule, which
would be beyond the limits of detection for the most advanced mass spectrometers. This
makes the detection and subsequent investigation of the mistranslated species unlikely
without utilising specific extraction and pre-concentration/sample enrichment techniques.
Another important consideration for the study of misincorporation is the suitability of
the models (yeast/E. coli/mammalian cell lines) and the time frame which is appropriate for
sufficient incorporation for detection versus the transient or acute effects on the proteome.
The use of animal models could be employed but resource limitations and time constraints
are often beyond that of most laboratories. While this review is focused on the study
of misincorporation, the investigation into misincorporational effects on the proteomic
landscape would also be important, as this could determine the underlying pathology
necessary to classify systemic disease pathways (NPAA-pathology). This may help elab-
orate biological cases arising from exposure to NPAAs and help build upon biomarker
classification for individual NPAAs. When considering the complexity of NPAA pathology,
studies in cellular models may be limited in their application to human disease processes,
especially when perturbation of PTMs that have biological function occur Table 2.
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Table 2. Amino acids and their biological post translational modifications.
Site of Modification Letter Symbol Modification
Alanine A Acetylation, methylation, o-linked glycosylation
Arginine R Acetylation, ADP-ribosylation, Citrullination, Hydroxylation, Methylation, Nlinked-glycosylation, Phosphorylation
Asparagine N Acetylation, ADP-ribosylation, Citrullination, Hydroxylation, methylation,N-linked-Glycosylation
Aspartic acid D Acetylation, Caspase cleavage, Hydroxylation, N-linked glycosylation,Phosphorylation
Cysteine C Acetylation, ADP-ribosylation, methylation, Nitration, Oxidation,Palmitoylation, Prenylation, S-nitroylation, Ubiquitination
Glutamic acid E Acetylation, Caspase cleavage, Hydroxylation, N-linked glycosylation,Phosphorylation
Glutamine Q Methylation
Glycine G Acetylation, Caspase cleavage, Hydroxylation, N-linked glycosylation,Phosphorylation
Histidine H Acetylation, Caspase cleavage, Hydroxylation, N-linked glycosylation,Phosphorylation
Isolecine I Acetylation, Caspase cleavage, Hydroxylation, N-linked glycosylation,Phosphorylation
Leucine L Hydroxylation, methylation
Lysine K Acetylation interruption(mass)
Methionine M Acetylation, Fromylation, Methylation, oxidation, Ubiquitylation
Phenylalanine F Acetylation, Caspase cleavage, Hydroxylation, N-linked glycosylation,Phosphorylation
Proline P Acetylation, Hydroxylation, Methylation, O-linked Glycosylation
Serine S Acetylation, Methylation, N-linked & O linked Glycosylation, Palmitoylation,Phosphorylation, Prenylation, Sulfation
Threonine T Acetylation, Methylation, O-linked glycosylation, Palmitoylation,Phosphorylation, sulfation
Tryptophan W Hydroxylation, Methylation, Prenylation, Ubiquitylation
Tyrosine Y Acetylation, Hydroxylation, Nitration, O-Linked Glycosylation,Phosphorylation, Sulfation
Valine V Acetylation, Hydroxylation
The table provides context for how a misincorporation at a particular site could have large biological impacts in cell function [58].
Detection of NPAA incorporation in humans may only be possible in individuals
exposed to a subtoxic intake of a NPAA over a prolonged time of many years i.e., supple-
mentary intake of norvaline in bodybuilders [59], azetidine (from beta vulgaris) in meat and
milk consumers [60], and Parkinson’s disease patients undergoing L-DOPA therapeutic
treatment [15]. However, when compared to cell lines and bacterial models, samples are
not as readily available. Choosing overexpression models is not a biologically relevant
methodology but it will give an approximate representation of the incorporation rate of
NPAAs, and researchers should use caution when drawing inferences between organisms
and human disease. The impact on cellular systems in multicellular organisms will be
different from that of single cellular models and will not consider the larger repertoire of
proteostasis mechanisms.
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5. Sample Processing and Enrichment
Sample processing and enrichment techniques are critical to ensuring that downstream
analytical methods have the optimal chance of detecting low abundance proteoforms, such
as those containing NPAAs. All the techniques presented here can increase the chance of
identification, however, the success of all MiP experimental approaches will be limited by
the amount of the NPAA containing species in the sample. Therefore, most explorations of
NPAA’s have relied upon inference methods showing their presence but not sequence loca-
tion via methods including radiolabelling and amino acid assaying of hydrolysed proteins,
rather than direct localisation [40–46,48–55,57]. The use of fractionation, enrichment, and
depletion are essential, but the caveat is always the potential loss of target proteoform due
to the sample processing. As an example, the starting amount of protein used to examine
the acetylated proteome was reported as 15mg to assay several thousand peptides [61],
whilst typical shotgun proteomic experiments are performed on several micrograms. To
this end, quantifying the amount of NPAA using radiolabels or hydrolysate amino acid
analysis can infer the amount of starting protein that is required and if the NPAA is indeed
present in a sample prior to the MiP workflow employed.
The enrichment of proteoforms containing a NPAA can employ various strategies
including; antibodies (pull-downs), metal and chemical affinities (chromatography), or
fractionation that concentrates targeted species. Antibody-based affinity enrichment is
often the first choice of enrichment for PTM studies [62] and requires a highly specific
antibody. Antibodies are time-consuming and expensive to create, especially for small
discrete chemical groups such as an amino acid side chain [63,64], therefore manufacture re-
quires considerable supporting evidence of specificity. Enrichment strategies such as metal
affinity as used in phosphopeptide enrichment may enrich an NPAA containing species,
although its application will be limited to those NPAAs whose chemistry is amenable to
binding.
Fractionation methods can help detect low abundance proteoforms or peptides and
the methodologies generally applied are based on molecular weight, charge, and hydropho-
bicity. The aforementioned methods do not specifically target peptides containing NPAAs
but may give a better chance at identification by dynamic range reduction and increase
in the amount of a specific proteoform or peptidoform. As NPAA incorporation may be
implicated in proteinopathies and neurodegeneration, enrichment of NPAA containing
proteoforms by isolation of insoluble proteoforms from cell lysates is an attractive selection
method that has been employed for such protein aggregates as β-amyloid and Tau [65].
Approaches to create sufficient levels of NPAA-containing proteins for detection
include the use of in vitro systems whereby protein production can be controlled, and high
levels of NPAAs introduced. The limitation with such approaches is that the organism
level disease pathology is not seen. An example of these methods is MS-READ [25] to
study NPAA incorporation into over-expressed GFP-elastin protein in E. coli or yeast. This
methodology is quoted as providing quantitation down to the 1/10,000 mistranslational
rate for canonical and NPAA species, applying the use of affinity columns to the GFP-
elastin protein and then chromatographic separation of all the captured species. This
model can establish a baseline of NPAA incorporation, but a mammalian cell line used
in the same manner will provide a closer estimate of the rate of incorporation specific
to human tRNA binding/proofreading. The NPAA BMAA has been investigated by
this method alongside tRNA binding studies that implicated incorporation in place of
alanine (contrary to past research identifying the site as serine [29]), with the product
being un-quantifiable [42]. Further complications arise when model systems such as E.
coli or yeast have alternate biological responses to an NPAA compared to mammalian
systems. For example, the response and misincorporation dynamics of BMAA in E. coli
appears markedly different than in mammalian cells [41], and E. coli are reported to have
yet unidentified mechanisms of avoiding misincorporation of this NPAA [66]. Quantitative
analysis of NPAA-modified versus native proteoforms is not currently possible as the
ionisation and chromatographic profiles (retention times) between the two peptide or
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proteoform species will differ. The amount of the modified proteoform can be inferred
from a loss of intensity in the unmodified species relative to the abundance of the other
proteotypic peptides assigned to the open reading frame, as shown in Figure 3. The
synthetic modification of all species is possible in certain instances where the chemistry is
simple, such as the addition of a hydroxyl group to Tyrosine to form the NPAA L-DOPA
with the subsequent use of heavy labelled oxygen supplied via peroxide to allow relative
comparison. This method has been applied for methionine oxidation [67]. In the same
manner, the synthesis of NPAA-containing peptides could be used to quantify the amount
if the target species is known. This approach has been applied to the study of the entire
human proteome by the Kuster lab and JPT peptides, who have synthesised all human
peptide sequences and acquired LC-MS/MS orbitrap data to form a pan-human spectral
library and the tool PROSIT [68].




Figure 3. How to compare mistranslated sequence abundances. Within a “Control” vs. “Treated” sample it is only possible 
to estimate the relative amount of the modified peptide species by a concurrent decrease in the amount of the unmodified 
peptide. This in essence is a decrease in the proteoform-typic peptide in comparison to the native proteoform-peptides. 
Abundance is only directly comparable between identical species. Conversely, the 
ionisation efficiency of the modified sequence will not reflect the missing amount of un-
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6. Mass Spectrometric Technologies
The current state of the art in proteomic technologies has lowered the amount of
sample required to less than a microgram for a comprehensive shotgun proteomics analysis,
however the linear dynamic range has stretched marginally to approximately four-five
orders of magnitude in orbitrap mass spectrometers [72]. There are many ways to increase
sensitivity to identify and selectively sequence these lower abundance ions. For confident
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spectral identifications and resolving of parent mass ions, a High-Resolution instrument
like that of an FT-ICR/orbitrap or high-resolution Quadrupole-Time of Flight (Q-TOF)
should be used.
Generally, the peptides containing NPAAs are orders of magnitude lower in abun-
dance in comparison to the total proteome. As such without sample enrichment strategies,
novel instrument operation techniques, correct ion dissociation techniques, and the hard-
ware being able to intelligently operate, identification is simply not feasible. Herein, the
technologies concerning the mass spectrometer that can increase the identification of the
low abundance misincorporations will be covered: Mass spectrometer base requirements;
Untargeted (either Data-Dependent Analysis (DDA) or Data Independent Acquisition
(DIA)), Targeted single reaction monitoring (SRM) and multiple or parallel reaction moni-
toring (MRM/PRM), hybrid methods, and dynamic range optimisations.
7. Mass Spectrometer Base Requirements and Desirable Features
The advent of high-resolution accurate mass (HRAM) instruments has enabled the
discrimination of low abundance ions from background noise especially in the instances of
FT-ICR/FT-orbitrap. The higher resolution settings on the orbitrap of 240,000–1,000,000
FWHM can determine the exact elemental composition of an ion. When applying this to
peptide sequences, it becomes feasible to accurately identify not only the sequence but also
other chemical properties of the peptides. For example, the characteristic fragmentation
patterns under various energies and fragmentation types, revealing the presence of PTMs.
In Orbitrap instruments, this high resolution is usually sacrificed in MS2 acquisition
for speed as 17,500 resolution is used in standard DDA methods, in conjunction with
the high-resolution MS1 scan, allowing an accurate assignment of fragments to amino
acid sequence. Within the isolation window for precursor transmission accumulation and
fragmentation (1.4 Da in an orbitrap (± 0.7 Da)) there is a potential that the fragmented
species may be derived from more than one single ion population given the likelihood of
similar m/z ion species being found within the isolation window selected for fragmentation.
This produces chimeric fragmentation spectra that may confuse the correct assignment of
the precursor’s structure, although modern peak-picking algorithms somewhat overcome
this. This is critical when an investigation of MiP requires accurate assignment. A way to
further overcome this issue is BOXCAR which is explored below [73].
8. Data Dependent Analysis
Current untargeted exploration of the proteome by LC-MS/MS involves the use of
Data-Dependent Acquisition (DDA), a method of operating the mass spectrometer to
sequentially select from an initial precursor scan of the most abundant precursor species
for fragmentation. This mode of operation is an important foundation for data generation
as each MS/MS spectrum should be derived from a single precursor (excluding the afore-
mentioned chimeric spectra). However, DDA favours sequencing of the high abundance
peptides in the sample, precluding the detection of low abundance species without prior
offline enrichment, depletion, or fractionation. However, there are several ways to increase
the depth of observed ions by the addition of inclusion/exclusion lists to detect lower
abundance ions, but the generation of these lists requires prior knowledge of the sample
and NPAA containing species.
Due to the nature of ion accumulation and space charging effects, only a certain
number of ions can be measured in the MS1 scan and lower abundance ions are masked
by the presence of higher abundance ions [74,75]. The way in which one can identify low
abundance species, particularly of a NPAA containing peptide, is to limit the precursor mass
range using gas-phase fractionation to break up the ion current into smaller ranges [76].
This would turn a traditional acquisition using a 300–1500 m/z range into 2–7 mass ranges,
which are subsequently combined bioinformatically.
A more robust approach to sampling the ion current and limiting the dynamic range
transmitted is the usage of BOXCAR. Developed by the Mann lab, this can increase the
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dynamic range ten-fold for the detection of ions [77]. This methodology uses a precursor
ion scan to survey the ion species distribution across the mass range, with the mass range
subsequently divided into windows with each having the same ion auto gain control (AGC)
target. The number of these BOXCAR scans can be increased to further increase the number
of lower abundance ions that can be accumulated by narrowing the window while keeping
the same AGC target (which in our experience is three). This method is excellent for finding
low abundant species but does not increase the ion accumulation of low abundance species
for a MS/MS scan, increasing the probability of their identification. Furthermore, the
BOXCAR scans occupy a significant amount of duty cycle time, limiting the number of pre-
cursor ions that can be fragmented. Jenkins and Orsburn’s preprint on BOXCAR-assisted
mass fragmentation (BAMF) offers key insight into how partial ion stream sampling can
increase the depth of identification when combined with fragmentation [75]. The benefit of
low abundance ion identification is that it allows larger spectral libraries to be created and
queried. A realised version of this methodology was also developed by the Gygi lab and
similarly limits transmission by using parallel-notched waveform isolation [78].
The incorporation of targeting can be used concurrently in a DDA experiment and
added to the mass spectrometer’s cycle time. The usage of targeting lists requires prior
knowledge of the peptide species that could contain an NPAA, and this can be generated
in silico by taking currently identified species of highly abundant and confidently matched
peptides, then adding the mass difference that incorporation would theoretically produce
to create a theoretical precursor mass for targeting. However, without knowledge of the
chromatographic elution profile, the target list cannot be scheduled, and thus the length
of the list must be restricted to manage duty cycle with expected chromatographic peak
width to ensure sufficient measurements across the peak, as well as differentiating isobaric
peptides being detected at differing retention times over the duration of chromatographic
separation. This issue of ions similar to the targeted precursors being detected during
the chromatographic separation can be overcome by using the targeting mode within
MaxQuant Live [79] that can dynamically warp global targeting lists. Dynamic warping
of targeting lists combats retention time drift that is apparent in intra sample injections as
the gradient conditions may have been slightly altered causing drift and a potential loss of
the targets during a separation. There is also a function built-in called BatMode enabling
fragmentation of the targeted precursor mass during every duty cycle for the predicted
elution window. This method utilises mass inclusion lists for fragmentation which can be
implemented on any Q-Exactive mass spectrometer that can perform DDA and handle
targeting schemes, which in turn decreases the limits of detection.
9. Data Independent Acquisition
Data independent proteomic approaches offer an increased depth of quantitative
analysis with the ability to generate a permanent digital ion record of the entire sample
being analysed [80]. The drawbacks of this technology are the reliance on generated
spectral libraries from DDA sample analysis, which are necessary for searching, and the
computational overhead required to generate them. For human samples, a synthetic library
of peptides that have been fragmented in an orbitrap instrument has been used to create
the PROSIT tool [68]. This allows the researcher to download a spectral library based on a
FASTA file provided and align it to the retention times of the instrument. This increases the
identification rate by using “match between runs” in various software and increases the
richness of the data acquired as exemplified by studies on the PTM phosphorylation [81].
Unfortunately, NPAA containing peptides are not present in the various databases
of PROSIT and SRM/human peptide atlas. Acquiring data in a DIA manner will allow
retrospective interrogation for these peptides, with a caveat that the amount of NPAA-
containing peptides present for analysis must be above the lower limits of detection. The
ways to overcome the lack of theoretical data available to predict the effect of NPAA incor-
porations on produced MS/MS spectra is through the use of tools (such as DeepLC [82])
that enable the prediction of retention times and elution windows for these unknown
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species. This allows smarter scheduling and the ability to potentially target tens of thou-
sands of precursors in a single injection. In the data analyses section of this manuscript, the
tools that can be used for in silico mining will be covered.
10. Immonium Ion and Precursor Ion Scanning
The use of precursor ion scanning in combination with stable isotope labelled amino
acids was developed by Purcell and Williamson [83]. This technique relies upon a diagnos-
tic immonium fragment ion that is unique to an amino acid. In the classical method, stable
isotope labelled analogues are used in cellular treatment and produce mass shifted product
ions. In this instance, it relies upon the NPAA to produce a unique product ion such as an
immonium ion (a fragment resulting from the amino acid side chain). If an immonium ion
is formed from the NPAA of interest, it is then feasible to use a stable isotope containing
NPAA, such as N-15, during treatment to produce this “diagnostic ion”. The size of certain
immonium ions may be below the scanning range in most general shotgun proteomic
experiments, which may require specific operational parameters and precludes the use of
certain instruments.
11. Ion Mobility Mass Spectrometry
A highly desirable feature for the analysis of MiPs and even PTMs is ion mobility
separation devices (IMS) available on several state-of-the-art mass spectrometric platforms,
with most major vendors offering a variation. For a review on the different types of IMS
please see: [84]. For further reading, see [85–87] and for example of novel usage, refer to [88].
In theory, NPAA containing sequence isomers could have the same m/z and potentially
same elution time in chromatography producing chimeric fragmentation spectra and being
indistinguishable in traditional proteomic LC-MS/MS methods. IMS offers the ability
to further separate ions using the third dimension of Collisional Cross Section (CCS) to
separate isobaric, co-eluting peptides. While there are several variants of IMS, there are
three variants commonly used with MS/MS that would be best suited: traveling wave
ion mobility spectrometry (TWIMS), drift-time ion mobility spectrometry (DTIMS), and
trapped ion mobility spectrometry (TIMS). TWIMS and DTMS determine mobility via how
the ions drift in a cell filled with gas, with the only difference being the application of
voltage in DTMS. TIMS determines mobility by trapping the ions in place and having gas
pass through the cell. IMS may overcome chimeric spectra production and distinguishing
precursors and products [74] but its immediate usage is to increase the depth of analysis of
a sample by fractionating the ion current. Implementing any of the approaches mentioned
within this manuscript in combination with IMS could provide high-quality empirical data
for the incorporation of NPAAs.
12. When Is an Incorporation Real?
When performing PTM or MiP analysis, it is important to establish parameters for
correct positive identification of a modified spectra that are sensible. The requirements are
a statistically significant peptide sequence identification, based on robust and established
statistical analysis and false discovery rate determination [11,89–94]. Positional fragments
for the NPAA in an MS/MS spectrum are mandatory for site localisation, similar to the
Ascore developed to account for sequence isomers in phosphoproteomic experiments [95].
On the rare occasion that sequence isomers elute together and form a chimeric spectrum,
it may not be possible to assign a localisation for the site of misincorporation. The next
level of identification should be that of a spectrum matching the unmodified peptide
existing within the sample, showing that the peptide belongs to the parent protein or open
reading frame. The prime consideration should be the peptide’s presence exclusively in
the conditions where misincorporation can occur otherwise, an identification is likely a
false positive. As the search space is increased to allow multiple variable modifications on
a single peptide, the chances of a forced match/false positive occurring become statistically
likely.
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13. Data Analysis Techniques
Once the acquisition of data has been performed, the most time-intensive part of
a proteomic experiment begins, that of data analysis. A typical proteomics experiment
will employ packages or pipelines that will perform the general required processing,
precursor/fragment extraction, centroiding, and mass recalibration. The spectra will
then either be searched directly against an in-silico generated tryptic digest database
created from the FASTA files for the relevant organism/s and Peptide-Spectrum Matches
(PSMs) validated through statistical models or through de novo sequencing of the spectra
performed with or without reference to a database.
The repurposing of proteomic tools to specifically explore MiP involves the mass
shift of the NPAA incorporation being known at each position of incorporation. Tools
that can consider the NPAA as a “PTM” by indicating it as a variable modification in
traditional database searching is possible if incorporation is at a high enough abundance
to produce an MS/MS spectrum of sufficient quality and the substitution position is
correctly characterised. These mass shifts for literarily relevant NPAA incorporations are
listed in Table 3, and for further reading on NPAAs, see [96–98]. Traditional database
searching is heavily reliant on the database using a known variable modification to identify
NPAA species and as such, a method known as “open” searching is recommended for
MiP exploration as it allows an exploration of the NPAA’s presence at multiple sites and
positions in an unbiased manner. The underlying flaw of traditional database searching is
still not resolved using spectral libraries in DIA. For identification of a NPAA containing
species to be possible in DIA the reference database still must have identified the peptide,
it is foreseeable that bioinformatically this problem could be addressed by the assignment
of unassigned, co-eluting set of fragments that perfectly align in retention time in relation
to the identified unmodified species.
Table 3. Toxic NPAAs, their canonical amino acid homologue, disease, and mass shift for incorporation.





































carboxylic acid Proline −14.0157 56.05002 MS [19]




Canavanine Arginine +1.9793 131.0933 MS/Systemic lupuserythematosus [106]
Jack bean plant (Canavalia
ensiformis) [107]
Norleucine Methionine −17.9564 86.09697 NNAD Bacteria
Mimosine Tyrosine +16.9902 153.0664 NNAD
Leucaena (Leucaena spp.)
and some Mimosa species
[108]
NMS stands for no mass shift. NNAD stands for no named associated disease and * denotes NPAAs that are formed via oxidation of a
proteogenic AA. Calculated theoretical immonium ions were assumed to be in positive ionisation mode.
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Several programs that have been developed that can perform open searching on
datasets. These programs have developed ways to restrict the computational search space
considered to localise PTMs in unmatched spectra. The main examples include; Frag-
pipe [109], MetaMorpheus [91], Open-pfind [110], tagGraph [111], Peaks Studio [112],
Proteome Discoverer [113], Byonic [114], MaxQuant [92], for more examples see Table 4.
These programs are essential to the exploration of NPAA localisation within the proteome.
As an example, we will cover a method that has been developed for systematic detection
of amino acid substitutions that does not rely on the use of a genetically altered or mod-
ified cellular expression system [8,25,42] and does not require the use of stable isotope
labelling [115].
Table 4. Tools for proteomic analysis that can be used in the pursuit of MiP.
Program GUI Cost Open Searches Accessibility DIA Searching Paper
Byonic Yes Licensed Yes Easy No [114]
EncyclopeDIA Yes Free No Easy Exclusively [116]
Fragpipe
Yes Free to academics Yes Easy Yes [109]Msfragger, Philosopher,
PTMShepard
Galaxy P Yes Free No Intermediary Being implemented [117]
Mascot Yes Licensed No Easy No [118]




peptides Intermediary No [92]Andromeda
MetaMorpheus Yes Free Yes Intermediary No [91]
OpenMS Yes Free Yes * Advanced Yes [120]
Open-pFind Yes Free Licensed Yes Easy No [110]
Peaks Studio Yes Licensed Yes Easy Yes [121]
Protein Pilot, PeakView Yes Licensed Yes: Protein Pilot Easy Yes: PeakView [122]
Proteome Discoverer Yes Licensed Through Nodes Easy Yes [123]
R workflows * Yes Free Yes Advanced Yes [124]
Skyline
Yes Free N/A Intermediary No [125]Signal quantification (DIA,
MRM, PRM)
SpectroMine
Yes Licensed Yes Easy No [126]
PTM Shepard
Spectronaut Yes Licensed No Easy Yes [127]
TagGraph No Free Yes Advanced No [111]
Trans-Proteomic Pipeline
Yes Free Yes Advanced No [128]
PTMProphet
GUI: Graphical User Interface. * Consultation of Bioconductor resources is recommended for a grounding in R implemented workflows.
Engine/algorithm names are italicised.
The methodology developed by Mordret et al. [11] relies upon a “blind modification”
search and repurposes the MaxQuant “dependent peptides” search to explore amino
acid substitutions [129]. This methodology could be repurposed in a NPAA exposure
model with subsequent identification of incorporation, given a large enough starting
sample with known NPAA protein association. This methodology employed two forms
of fractionation, solubility and strong cation exchange, which can be routinely performed
by most laboratories. The peptide search relies on the principle that the modified peptide
sequence will be of lower abundance compared to the identified unmodified counterpart,
the peptides that are assigned to known modifications from the Unimod database are
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filtered out and peptides remaining unexplained are considered for NPAA incorporation.
Within Mordret’s paper they were also able to align chromatographic elution profiles for
substituted amino acids which could be used to determine the elution profiles of NPAA
species. This paper provides the best pipeline for analysing NPAA containing proteomes
and is highly recommended for the investigation of the MiPome.
14. Conclusions, a Future Direction and a Best Practice for MiP
Outlined throughout this paper are ways to increase the identification of NPAA
containing species and have framed this as mistranslational proteomics or MiP. Key consid-
eration should be given to the sample selection and model creation that offer the highest
level of misincorporation, and it is advised that the investigating lab employs amino acid
analysis on the proteome prior to committing resources to proteome analysis. The next
step in a workflow is to employ an enrichment method or fractionation to further reduce
the dynamic range of protein abundance. It is noted here that development of a specific
enrichment method may be required, either chemical or an antibody-affinity based. Investi-
gators are also cautioned against the use of peptide labelling tags for use in NPAA peptide
identification.
It was outlined that operation of a mass spectrometer that can transmit a smaller mass
range of ions to increase the dynamic range, such as that of BOXCAR or parallel-notched
wave form isolation, will enhance the depth of identification and that IMS can be used
to further separate out NPAA containing species from higher abundance peptides and
separate chimera producing sequence isomers. The data analysis workflow is the key to
whether a NPAA containing species will be identified, and several programs are listed
that can perform open searches that can be used to explore the MiPome. Furthermore,
a complete pipeline was identified that can be employed for the investigation of NPAA
proteoforms systematically without the requirement of genetically modified models or use
of expensive stable isotopic reagents.
The further progression of the entire field of proteomics towards the study of pro-
teoforms will continue to increase the ability to detect and quantify the MiPome, which
will provide insight into how disease related to NPAA incorporation progresses and infer
potential treatments.
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